FY2024 EPS Forecast for Regulus Therapeutics Cut by Analyst

Regulus Therapeutics Inc. (NASDAQ:RGLS) – Investment analysts at HC Wainwright dropped their FY2024 earnings estimates for Regulus Therapeutics in a report released on Monday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings per share of ($0.86) for the year, down from their previous forecast of ($0.80). HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Regulus Therapeutics’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Regulus Therapeutics’ Q4 2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.23) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.95) EPS.

A number of other research firms have also issued reports on RGLS. StockNews.com raised shares of Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. Oppenheimer reissued an “outperform” rating and set a $7.00 target price on shares of Regulus Therapeutics in a research note on Wednesday, August 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Regulus Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $10.80.

Regulus Therapeutics Trading Down 4.7 %

Shares of Regulus Therapeutics stock opened at $1.43 on Thursday. Regulus Therapeutics has a 1 year low of $1.08 and a 1 year high of $3.79. The company has a market cap of $93.67 million, a P/E ratio of -1.34 and a beta of 1.63. The stock has a 50-day moving average price of $1.55 and a 200 day moving average price of $1.81.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03).

Institutional Investors Weigh In On Regulus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of RGLS. NEA Management Company LLC bought a new stake in shares of Regulus Therapeutics during the 3rd quarter worth about $10,154,000. RA Capital Management L.P. bought a new stake in Regulus Therapeutics during the first quarter worth approximately $18,000,000. Point72 Asset Management L.P. bought a new stake in Regulus Therapeutics during the third quarter worth approximately $1,403,000. Vanguard Group Inc. grew its holdings in Regulus Therapeutics by 158.4% during the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after purchasing an additional 453,784 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of Regulus Therapeutics in the second quarter valued at approximately $352,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.